Full Year 2023 GAAP Revenues of $1.147 billion
Full Year 2023 GAAP net loss of $20 million and GAAP net loss per diluted share of $0.45
Full Year 2023 Non-GAAP EBITDA of $138 million and Non-GAAP net.
Advanced Services for Central Pharmacy Dispensing Designed to Support Dispensing Accuracy and Patient Safety while Improving Clinical and Financial Outcomes
.
Download PDF Advanced Services combine innovative technology, expertise, and intelligence intended to support business and clinical outcomes across all settings of care.
05.12.2022 - Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that it will showcase the Company’s Advanced Services at this . Seite 1